Feasibility of a Centralized, Pharmacy-Led Penicillin Allergy Delabeling Program

被引:6
|
作者
Antoon, James W. [1 ,2 ]
Grijalva, Carlos G. [5 ]
Grisso, Alison G. [8 ]
Stone, Cosby A. [3 ]
Johnson, Jakobi [1 ]
Stassun, Justine [1 ]
Norton, Allison E. [4 ]
Kripalani, Sunil [6 ,7 ]
Williams, Derek J. [1 ]
机构
[1] Monroe Carell Jr Childrens Hosp Vanderbilt, Div Hosp Med, Nashville, TN USA
[2] Vanderbilt Univ, Dept Pediat, Sch Med, Nashville, TN USA
[3] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy & Immunol, Nashville, TN USA
[4] Vanderbilt Univ, Med Ctr, Dept Pediat & Med, Nashville, TN USA
[5] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, Nashville, TN USA
[6] Vanderbilt Univ, Med Ctr, Dept Med, Div Gen Internal Med & Publ Hlth, Nashville, TN USA
[7] Vanderbilt Univ, Ctr Clin Qual & Implementat Res, Med Ctr, Nashville, TN USA
[8] Monroe Carell Jr Childrens Hosp Vanderbilt, Dept Pharm, Nashville, TN USA
基金
美国国家卫生研究院; 美国医疗保健研究与质量局;
关键词
D O I
10.1542/hpeds.2021-006369
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BACKGROUND Penicillin allergy labels are often inaccurate in children and removing unnecessary labels results in improved outcomes and lower health care costs. Although the hospital setting is a frequent point of contact for children, strategies to evaluate penicillin allergies in the hospital are lacking.METHODS We performed a prospective pilot study to determine the feasibility of a centralized, pharmacy-led approach to penicillin allergy evaluation. Children with a reported history of penicillin allergy admitted to our children's hospital were risk-stratified and those stratified as low-risk underwent a single-dose oral challenge by a central pharmacist, regardless of the need for antibiotics. After the completion of each patient's delabeling process, surveys were distributed to health care personnel involved in the patient's care to collect perceptions on the acceptability, appropriateness, and feasibility of this intervention. Measures were scored by using a 5-point Likert scale.RESULTS Of the 23 patients who screened as low-risk, 20 underwent a penicillin allergy evaluation and an oral challenge. Of these, the penicillin allergy label was removed in 19 (95%) patients (Fig 1). The median age was 7 years (range 11 months-18 years). Participants rated the risk stratification and delabeling favorably overall, with high ratings on all 3 implementation measures: acceptability (mean 4.55, +/- standard deviation [STD] 0.65), appropriateness (mean 4.58, STD +/- 0.6), and feasibility (mean 4.51, STD +/- 0.73). Measures of acceptability, appropriateness, and feasibility remained high when stratified by health care worker type and provider type.CONCLUSIONS Our findings provide support for systemic implementation of penicillin allergy delabeling strategies in hospitalized children.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Delabeling Without Testing in a Pharmacy-led Inpatient Penicillin Allergy Evaluation Program
    Brown, Jordana
    Kaddis, Timothy
    Ham, YoungYoon
    Joshi, Shyam
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB40 - AB40
  • [2] Effectiveness and feasibility of a penicillin allergy delabeling program in the postacute inpatient rehabilitation setting
    Galipean, Joseph
    Jacob, Jerry
    INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2024, 45 (11) : 1370 - 1372
  • [3] Evaluation of a Pharmacist-Led Penicillin Allergy Assessment Program and Allergy Delabeling in a Tertiary Care Hospital
    Turner, Nicholas A.
    Wrenn, Rebekah
    Sarubbi, Christina
    Kleris, Renee
    Lugar, Patricia L.
    Radojicic, Christine
    Moehring, Rebekah W.
    Anderson, Deverick J.
    JAMA NETWORK OPEN, 2021, 4 (05)
  • [4] Update on penicillin allergy delabeling
    Shaker, Marcus
    McWilliams, Samuel
    Greenhawt, Matthew
    CURRENT OPINION IN PEDIATRICS, 2020, 32 (02) : 321 - 327
  • [5] AN EVALUATION OF A PHARMACY-LED MEDICATION MANAGEMENT PROGRAM TO IMPROVE PHARMACY PERFORMANCE
    Desai, R. A.
    Turner, K.
    Shea, C.
    VALUE IN HEALTH, 2019, 22 : S325 - S325
  • [6] Delabeling of Penicillin Allergy: Room for Improvement
    Fransson, Sara
    Damving, Christina Monnerup
    Boel, Jonas Bredtoft
    Arpi, Magnus
    Skinhoj, Ida Gjorup
    Jarlov, Jens Otto
    Mosbech, Holger F.
    Poulsen, Lars K.
    Garvey, Lene H.
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2023, 184 (09) : 870 - 874
  • [7] Penicillin Allergy Delabeling Program: an exploratory economic evaluation in the Australian context
    Brusco, Natasha K.
    Bury, Susan
    Chua, Kyra Y. L.
    Vogrin, Sara
    Holmes, Natasha E.
    Trubiano, Jason A.
    INTERNAL MEDICINE JOURNAL, 2023, 53 (01) : 74 - 83
  • [8] Penicillin Allergy Delabeling: A Multidisciplinary Opportunity
    Staicu, Mary L.
    Vyles, David
    Shenoy, Erica S.
    Stone, Cosby A.
    Banks, Taylor
    Alvarez, Kristin S.
    Blumenthal, Kimberly G.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (09): : 2858 - +
  • [9] Clinical Outcomes of a Pharmacy-Led Blood Factor Stewardship Program
    Trueg, Anne O.
    Lowe, Christopher
    Kiel, Patrick J.
    AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (06) : e643 - e647
  • [10] Implementation and Assessment of a Pharmacy-Led Inpatient Transitions of Care Program
    Evans, David
    Usery, Justin
    SOUTHERN MEDICAL JOURNAL, 2020, 113 (06) : 320 - 324